Get started
JEFFERIES FINL GRP DL 1JEFFERIES FINL GRP DL 1JEFFERIES FINL GRP DL 1

JEFFERIES FINL GRP DL 1

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

LN3 trade ideas

JEF Jefferies Financial Group Options Ahead of EarningsIf you haven`t bought JEF before the previous earnings: Now analyzing the options chain and the chart patterns of JEF Jefferies Financial prior to the earnings report this week, I would consider purchasing the 62.50usd strike price Calls with an expiration date of 2024-10-18, for a premium of approximately $2.00. If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
NYSE:JEFLong
by TopgOptions
JEF Jefferies Financial Group Options Ahead of EarningsIf you haven`t sold JEF before the previous earnings: Then analyzing the options chain and the chart patterns of JEF Jefferies Financial Group prior to the earnings report this week, I would consider purchasing the 45usd strike price at the money Calls with an expiration date of 2024-5-17, for a premium of approximately $2.02. If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
NYSE:JEFLong
by TopgOptions
Jefferies May Be Nearing a BreakoutJefferies Financial has been a tight range near old highs, and some traders may expect a breakout soon. The first item on today’s chart is the ascending triangle since 2024 began. The investment bank was initially trapped under $41, but more recently has pushed above that level. Is it breaking the continuation pattern to the upside? Second, JEF is near the previous record high of $42.29. Investors could monitor that level for confirmation of a longer-term acceleration. Third, earnings beat estimates last month. MACD was falling at the time, which may explain why the stock consolidated instead of climbing. However, the oscillator turned up last week. That may suggest momentum is getting more bullish again. Finally, the 8-day exponential moving average (EMA) has remained above the 21-day EMA since early November. TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. See our Overview for more. Important Information Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options, futures or cryptocurrencies); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission (“SEC”) and a futures commission merchant licensed with the Commodity Futures Trading Commission (“CFTC”). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association (“NFA”), and a number of exchanges. TradeStation Crypto, Inc. offers to self-directed investors and traders cryptocurrency brokerage services under federal and state money services business/money-transmitter and similar registrations and licenses. TradeStation Securities, Inc., TradeStation Crypto, Inc., and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., all operating, and providing products and services, under the TradeStation brand and trademark. TradeStation Crypto, Inc. offers to self-directed investors and traders cryptocurrency brokerage services. It is neither licensed with the SEC or the CFTC nor is it a member of NFA. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.
NYSE:JEF
by TradeStation
JEF Jefferies Financial Group Options Ahead of EarningsIf you haven`t sold JEF here: Then analyzing the options chain and the chart patterns of JEF Jefferies Financial Group prior to the earnings report this week, I would consider purchasing the 37.50usd strike price Puts with an expiration date of 2024-1-19, for a premium of approximately $2.12. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.
NYSE:JEFShort
by TopgOptions
JEF Jefferies Financial Group Options Ahead of EarningsIf you haven`t sold JEF here: Then Analyzing the options chain of JEF Jefferies Financial Group prior to the earnings report this week, I would consider purchasing the $32.5 strike price In the Money Puts with an expiration date of 2023-7-21, for a premium of approximately $1.75. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.
NYSE:JEFShort
by TopgOptions
Big Upcoming Earnings PlaySupport line is touched 7 times in 7 days and did not break once. Earnings Suprise of 51%. Trading day before earnings were released, we saw a rise and then we hit the weekend. October 4th opened 38.25 and sold off to the 30.90 zone but last candle of the day was a doji formed a support. The 5th rolled around, and we had a green candle that ate the last 3 red candles. It wasn't until the 6th that we saw a huge uptrend. Trend arrow straight from rise on the 6th to the top of resistance on the third line was tested once and bounced and the second time it tested it formed a support that touched 6 times until we saw a surge to a high of 44.45 and then saw a sell off. Same support line as day of earnings. Key reversal as we near upcoming earnings-11 days out. With big surprises from the last 4 quarters TTM if we see in the next 11 days pass the 38.98 and form a new support then we saw stock price growth from last quarter putting us in a good zone for stock to pass or near new high from the 44 zone. My buy point for calls is going to be after earnings due to prior earnings sell off same day at end market if there is a big Suprise I will but towards close of day following trend of last earnings report. Last 3 earning dates we saw after hour earnings of high surprises, and they seem to pop big after the dip of end day earnings report backing my buy point. -LETS ALL START OFF ON A GOOD NEW YEAR> YOU WILL ALL BE MILLIONARIES-THIS IS YOUR YEAR> EARNINGS REPORT IS JANUARY 4TH BUY POINT IS JAN 5TH RIDE AROUND 3-12 DAYS
NYSE:JEFLong
by haydencrann
JEF (Jefferies Financial Grp) - Bullish finish to quarterJefferies Financial Group Inc. is a diversified financial services company. It engaged in investment banking and capital markets, merchant banking and an alternative asset management platform. The company's financial service businesses are Berkadia which provide commercial mortgage banking, investment sales and servicing; Leucadia Asset Management provide asset management; HomeFed provide a publicly traded real estate company, FXCM provides online foreign exchange trading services and Foursight Capital provide vehicle finance. Jefferies Financial Group Inc. formerly known as Leucadia National Corporation is based in New York, United States. Analysis/Commentary Strong EPS and Sales Growth Y-on-Y Based on the study of the previous quarterly earnings reports and subsequent price moves: - Current quarter has given price move up to the LOW point - Expect some pause prior to push - Expectation for the price to then move up to MED TARGET by quarter end - Trailing stop-loss on price above LOW point GOOD LUCK. DO YOUR OWN RESEARCH!
NYSE:JEFLong
by kennzo
$JEF takes a breath, moves sidewaysIn our Monday morning pre market Flight Path newsletter we took a look at $JEF. We mentioned that with the financials sector running up against long term resistance we may see a pause in names like Jefferies Financial Group. Indeed, we saw short term counter trend red arrows signaling that momentum having been overbought was now cooling off. 
While we haven’t seen much of a correction against the trend since Monday but we have indeed seen a pause, a sideways consolidation.
NYSE:JEF
by GoNoGoCharts
Ignore! Chart for couple friends that asked for quick reviewI have only looked at this stock for about 15 mins for a couple of friends that were told to buy it per their broker. Do not trade this from my chart as I have not worked on this enough to post for public review. Thanks a good trading OK, here you go Brent & Mike....hope this helps web.tmxmoney.com Jefferies to Lead Urgent Initiative to Raise up to $1 Billion in Private Capital to Support Newly Announced Public-Private Partnership Developing a High-Volume Emergency Drug Packaging Solution on U.S. Soil NEW YORK Jefferies Financial Group, Inc. (NYSE: JEF) today announced it is the first private-sector company to support a newly established public-private consortium launched by the U.S. Department of Health and Human Services (HHS) through its Office of the Assistant Secretary for Preparedness and Response (ASPR). HHS joined with ApiJect Systems America (ApiJect), a public-benefit corporation, to create a U.S.-based high-volume, “surge” drug packaging solution using Blow-Fill-Seal (BFS), which is a process used in sterile manufacturing facilities worldwide that features a small medical-grade plastic container that holds a prefilled volume of medicines or vaccines. This new consortium called RAPID – Rapid Aseptic Packaging of Injectable Drugs – is intended to establish critically needed surge capacity “to fill and finish, on a rapid basis, hundreds of millions of prefilled syringes to respond quickly and efficiently to widespread health emergencies, such as the novel coronavirus outbreak.” (HHS Public Announcement, March 18, 2020 www.hhs.gov) As the first private-sector entity to join this vital public health initiative, Jefferies will support the initiative by providing access to the firm’s vast client network, experienced management team, global financial resources and an immediate initial seed capital commitment of at least $10 million to jumpstart the RAPID network as quickly as possible. RAPID will build a domestic surge capacity network of up to eight packaging facilities using BFS. FDA-approved BFS technology is currently used to package billions of doses annually for medicines used to treat respiratory conditions, rotavirus oral vaccines and more. RAPID will combine this well-established technology with an innovative interlocking needle hub to achieve population-scale volumes of prefilled syringes. Jefferies leadership in the consortium provides immediate seed capital and an experienced global team to assist RAPID’s efforts to access the private-sector capital markets. This follows the March 18 announcement by HHS awarding ApiJect up to $456 million for the research and development of the BFS prefilled syringes and domestic network of year-round manufacturing facilities for population-scale surge response capacity during health emergencies. Rich Handler, CEO of Jefferies, and Brian Friedman, President of Jefferies, commented: “All of us at Jefferies are deeply concerned about, and personally impacted by, the COVID-19 pandemic. We are ready to put the firm’s capital to work in smart solutions, such as RAPID, that are critically needed to help America and the world win the battle against this pandemic. We have always supported new and innovative approaches and we believe RAPID is the right public-private partnership as we face this crisis in both the short term and long term.” Messrs. Handler and Friedman also noted, “Our support of RAPID puts us right where all leadership companies belong -- on the front lines of the war against this global threat. We need to be sure that when therapeutics and vaccines for COVID-19 become available health care professionals have the resources and ability to administer them quickly and effectively on a massive, global scale. We believe that ApiJect and RAPID’s goal of creating hundreds of millions of prefilled syringes will make that possible.” ApiJect CEO, Jay Walker, commented: “Given the urgency to bring back critical elements in the pharma manufacturing supply chain to the U.S., we are especially pleased to be leading the RAPID consortium. Drug packaging and dispensing at population scale within our borders will be essential to safeguard the American public quickly and safely. Winning this battle against COVID-19 requires each and every company, citizen and all levels of government to step up. Having Jefferies as RAPID’s initial, shoulder-to-shoulder supporter brings a global network of clients’ immediate seed capital and a deep and experienced team to expand RAPID’s management capabilities. Its substantial financial support signals to others in the investment community the vital and central role that RAPID, as a public-private partnership led by the HHS Assistant Secretary for Preparedness and Response, will play in the war against the current pandemic, as well as future health emergencies and threats.” About Jefferies Jefferies Financial Group Inc. is a diversified financial services company engaged in investment banking and capital markets, asset management and direct investing. Jefferies Group LLC, our principal subsidiary, is the largest independent, global, full-service investment banking firm headquartered in the U.S. Focused on serving clients for nearly 60 years, Jefferies is a leader in providing insight, expertise and execution to investors, companies and governments. Our firm provides a full range of investment banking, advisory, sales and trading, research and wealth management services across all products in the Americas, Europe and Asia. About ApiJect ApiJect Systems America is dedicated to making injectable medicines safe and available for everyone. By building a network using high-speed, high volume Blow-Fill-Seal plastics technology, we can supply hundreds of millions of ultra-low-cost pre-filled syringes in 30 days -- with optional RFID tags to enable GPS-based mobile tracking. ApiJect is currently contracted with the U.S. Government to create and manage the RAPID Consortium, which when fully funded and built out, will provide the capability to fill and finish up to 330 million pre-filled syringes per month to respond to national or smaller scale health emergencies. See ApiJect at www.rapidconsortium.com.
NYSE:JEF
by curazguy